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Without the advent of the new technology of whole genome sequencing, a genetic answer to AJ's weakness eluded researchers and clinicians. Titin is aptly named, due to its gigantic size. It is the largest known protein in the human body. Weighing in at 3.8 million Daltons and spanning 363 exons at a length greater than one micrometer, it is the heavyweight champion of all human proteins. It is estimated that there is as much as one pound of this protein present in an average human. Its enormous size made it unwieldy to sequence using the older Sanger sequencing methods. The very nature of AJ's genetic variant impeded its discovery.
In the months after receiving AJ's genetic diagnosis we were able to then cast a wider net and have extended family members tested. Several of AJ's aunts, cousins and an uncle tested positive for single allele variants in TTN. Although TTN as a cause of CNM was a new fi nding, it was well known that single variants in TTN are associated with a heart problem known as dilated cardiomyopathy (DCM). Further clinical examination of the wider family members revealed mild DCM in three of AJ's relatives with the TTN variant. Family members, including AJ, are now able to start treatment for DCM and/or undergo more careful monitoring of their cardiac status. Unlike the congenital myopathies, there are drug treatments that can help alleviate DCM symptoms and progression. This was an unexpected twist to our participation in the research and one that will likely have health benefi ts. This helpful fi nding is another positive result of our family's undergoing whole genome sequencing. It points to the benefi ts of genetic confi rmation to help treatable health outcomes. It will have an impact on the clinical monitoring that AJ will get during his lifetime.
Finally having this answer helps me to understand many aspects of my son's condition. I now know the gene mutation that is responsible and the protein that it impairs. I know how it was inherited and the risks for other family members. I can begin to understand the problem at the level of the muscle cell and its impact on muscle function. I am inspired to further our efforts in support of CNM research and potential future treatments to tame this ghost. I have a greater understanding of the medical conditions that AJ is at risk for and can cross off ones that he is not at risk for. I hope that our discovery advances the current understanding of CNM to benefi t all people with this variant. I am truly grateful to have had the opportunity to participate in the challenge. I am happy to have a genetic answer to our family's questions. Having a genetic diagnosis is not a fi nal destination on our medical journey, but it is a hugely important milestone along the way.
My Experience with Direct to Consumer Genetic Testing
Sarah M. Hartz A s a genetics researcher interested in learning more about direct to consumer genetic testing, I thought the best way to start studying this topic was to get myself tested by the various companies. At the time, there were four different companies that offered this service (23andMe, deCODE me, Navigenics and Pathway Genomics), so I sent a sample to each company to both experience the process and see how my results differed across companies.
The fi rst results that came back were from Pathway Genomics. I was shocked by the results that told me I have a very high genetic risk for macular degeneration, the most common cause of age related blindness. None of my family members has or has ever had macular degeneration, so these results surprised me. Coincidentally, at the time I got the results, I was at a meeting with an opthomologist who collected and manages one of the largest genetic databases for macular degeneration. I was anxious about my results, concerned that I was almost defi nitely going to go blind, so I approached her to talk about my results. When I told her my concern, she looked at me blankly because there really are no genetic determinants that increase your risk for macular degeneration to the point where you will defi nitively get the disease. She did not understand what the company could have tested that would justify my concern. That weekend, I started taking expensive eye vitamins.
Over time, I received my results from 23andMe, Navigenics and deCODEme. The results were strikingly different. Although I had an elevated risk for macular degeneration across the companies, my risk of macular degeneration was different for each company. Pathway Genomics reported that I should "be proactive" regarding my risk for macular degeneration. This is the highest risk option; the other two levels were "learn more" and "live a healthy lifestyle" (more recently, Pathway Genomics changed their risk levels to "average risk", "above-average risk", and "increased risk"). In contrast to the vague risk levels given by Pathway Genomics, the other three companies gave me probabilities for my estimated lifetime risk of macular degeneration: Navigenics gave me a 61% lifetime risk, 23andMe gave me a 38.1% lifetime risk, and deCODEme gave me a 90% risk.
Because I'm a medical researcher, I then investigated how it can be that these risk estimates are so wildly different from one another. I fi rst looked to confi rm that they genotyped the same genetic markers. This was the easiest thing to do because it the specifi c genotypes were in all of my reports. Then I looked to see if they used the same medical studies to compute the risk. These were also essentially the same. It turned out that the difference is the methods they used for calculation of risk. I had assumed that was the easy part because it's just a matter of multiplying numbers together, including baseline risk of macular degeneration, the joint impact of the genetic variants on this risk. It turns out that the problem is that we actually don't know the baseline risk of macular degeneration for people who don't have the genetic variants, and we don't know how the genetic variants interact with each other and the environment to lead to the development of macular degeneration. So, probably the most accurate result I received was "be proactive".
Prior to engaging in this exercise, I didn't realize how diffi cult and imprecise it is to calculate risk of disease that includes genetic information. It's interesting that although the science has come a long way towards identifying genetic risk factors of disease, we cannot translate these fi ndings to everyday medicine until we know how these risk factors contribute to the overall risk of disease at a personal level.
Many medical professionals and genetic researchers are against direct-to-consumer genetic testing because of the diffi culty with interpretation and potential for unnecessary medical procedures that may result from this information. How is it helpful, they ask, to have a test that should be interpreted as "be proactive"?
In general, we don't have precise probabilities for most things in medicine. Although medical studies result in risks that would give probabilities like 38.1%, the studies themselves are often in specifi c populations and under highly regulated conditions that don't easily apply to the general population. Many diagnoses are based on somewhat arbitrary cut points on a scale (for example high blood pressure, where there is a distinct range for normal blood pressure, a distinct range for high blood pressure, and a large grey area in between), or on a somewhat arbitrary number of related symptoms (for example dementia where a certain amount of forgetfulness is in the range of normal, and severe confusion under the right circumstances is clearly dementia, but again there is a large grey zone). Ideally, however, medical tests should help inform management of a patient. Does "be proactive" help us know who to screen more often? It may not.
While I was debating the utility of genetic testing, Navigenics and deCODEme closed, and the FDA shut down the 23andMe medical reports deeming that the report was acting as an unapproved medical device. Pathway Genomics still offers testing, although it is conducted through your physician (and has always been conducted this way; I served as my own physician). This regulation feels paternalistic to me, but it is a way of protecting consumers from over-interpreting the risk estimates in the 23andMe health reports.
The best word I have for describing my journey into direct-to-consumer testing is "confusing". I am confused about the risk interpretations; I am confused about the relevance of this for my health; and I am confused about whether limiting direct access to genetic testing is overly paternalistic. In the end, I just stopped taking my eye vitamins.
Illusions of Certainty
Carla C. Keirns On the fi rst meeting with the pediatrician at four days old, I asked when we should have his vision screened. My husband wears glasses without which he can barely get to the kitchen to get his coffee in the morning. I wore glasses from the age of six months into my teens, though I don't need them anymore. She said three months is as early as they can tell.
We sat in a nearly empty pediatric ophthalmologist's offi ce at 3 p.m. on Halloween (it's pretty easy to get an appointment while all the older kids are trick-or-treating). When we were called back, a medical assistant recorded the basic history-both parents had crossed eyes, lazy eyes, and wore glasses under a year old. She took out a dozen different toys to see if they could capture my son's attention. A rubber ducky lit up by a fl ashlight was the easiest, many others not so much. I'd noticed that at home, too. It was really hard to get him interested in playing with anything. Rattles, blankets, even teethers did not tempt him. We had one of those "baby activity" gyms where you can suspend toys above a baby lying on a blanket, and he can reach up, but my son had no interest.
The doctor came in and did an initial exam, then put in dilating drops.
As we went out to the waiting room, I had the sense he was holding back.
My son hated the drops. As he sat in the waiting room crying, my husband wanted to take him outside for a walk. "What?" I said, "They just put drops in his eyes, you can't take him out in the sun." My husband insisted, so I said only if he wore his sunglasses. Three-months-old in a onesie and the tiniest sunglasses you've ever seen, I couldn't decide whether he belonged in Miami, Southern California, or was an FBI agent in training.
After half an hour, we were brought back and the physician did a dilated eye exam, looked at our son's retinas, and checked his visual acuity. After he was done, he turned to us. I don't remember how he started, but I think he explained something about "blond retinas." He gave our baby boy a diagnosis of ocular albinism and said he was legally blind. After that, I became like a character on Peanuts, hearing what he said, but as if it was muffl ed by water or the incomprehensible noises that Charlie and Lucy's teachers are always making.
Blind! My heart started racing, and my thoughts swirled. What was he saying? What did this mean? Would he be able to read? Go to school? Make a living? What would happen to him? How could he be blind-he could clearly see, if not that well?
The doctor continued with a discussion of our options. We could go to Manhattan for Visual Evoked Potential testing to show how his optic nerves and tracts connected to the visual cortex of
